Ademetionine

Summary

Ademetionine (CHEMBL1088977) is a phase-3 clinical-stage small molecule (ATC A16AA02); indicated across 11 conditions including metabolic dysfunction-associated steatotic liver disease and intrahepatic cholestasis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A16AA02
• Indications: 11 conditions
• Clinical trials: 33
• Chemistry: 398.4 Da · C15H22N6O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1088977
Name	Ademetionine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	34755
ChEBI	CHEBI:67040
ATC	A16AA02
Molecular formula	C15H22N6O5S
Molecular weight	398.4
InChIKey	MEFKEPWMEQBLKI-AIRLBKTGSA-N

SMILES: C[S+](CC[C@@H](C(=O)[O-])N)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O

IUPAC name: (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-methylsulfonio]butanoate

ChEBI definition: A sulfonium betaine that is a conjugate base of S-adenosyl-L-methionine obtained by the deprotonation of the carboxy group.

Other ChEBI roles (chemical / environmental): human metabolite.

Also known as: Ademetionina, Ademetionine, Adenosylmethionine, Adomet, Moodplus, MSI-195, S-adenosyl-l-methionine, S-adenosylmethionine, SAM-E, SAME, Samyr 200, Transmetil

Patent coverage: 768 distinct patent families (1,522 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,488 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Protein arginine N-methyltransferase 6, 4’-phosphopantetheinyl transferase ffp, Adenosine receptor A3, Vascular endothelial growth factor receptor 2, Protein arginine N-methyltransferase 8, PRMT5/MEP50 complex, Protein arginine N-methyltransferase 7, S-adenosylmethionine decarboxylase proenzyme, Protein-L-isoaspartate(D-aspartate) O-methyltransferase, Phenylethanolamine N-methyltransferase.

Bioactivity

ChEMBL activities: 13 potent at pChembl ≥ 5 of 20 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CARM1	8.55	IC50	2.8	nM	CHEMBL_ACT_29270377
CARM1	7.38	IC50	42	nM	CHEMBL_ACT_29118079
ADORA3	6.76	AC50	173.8	nM	CHEMBL_ACT_25198662
PRMT1	6.33	IC50	468	nM	CHEMBL_ACT_29118073
PRMT7	6.31	IC50	491	nM	CHEMBL_ACT_29118085
PRMT8	6.12	IC50	759	nM	CHEMBL_ACT_29118088
PRMT5	6.1	IC50	793	nM	CHEMBL_ACT_29117966
PRMT6	5.9	IC50	1258	nM	CHEMBL_ACT_29118082
PNMT	5.32	Kd	4800	nM	CHEMBL_ACT_1845496
PRMT3	5.29	IC50	5175	nM	CHEMBL_ACT_29118076
PNMT	5.15	Kd	7100	nM	CHEMBL_ACT_1845497
PNMT	5.12	Kd	7500	nM	CHEMBL_ACT_1845502
PNMT	5.12	Kd	7500	nM	CHEMBL_ACT_1845506

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

11 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
metabolic dysfunction-associated steatotic liver disease	3	MONDO:0013209	EFO:0003095
intrahepatic cholestasis	3	MONDO:0019072	MONDO:0019072
liver disorder	3	MONDO:0005154	EFO:0001421
hepatitis	3	MONDO:0002251	HP:0012115
primary biliary cholangitis	2	MONDO:0005388	EFO:1001486
major depressive disorder	2	MONDO:0002009	MONDO:0002009
depressive disorder	2	MONDO:0002050	MONDO:0002050
alcoholic liver cirrhosis	2	MONDO:0006644	EFO:1000802
hepatitis C virus infection	2	MONDO:0005231	EFO:0003047
nicotine dependence	2	MONDO:0008575	EFO:0003768
hyperhomocysteinemia	1	MONDO:0004743	MONDO:0004743

Clinical trials

Total trials: 33.

Phase distribution

Phase	Trials
Not specified	13
PHASE2	5
PHASE4	4
PHASE3	4
PHASE1	4
PHASE2/PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01998620	PHASE4	UNKNOWN	Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis
NCT02557360	PHASE4	COMPLETED	Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis
NCT05363020	PHASE4	COMPLETED	S-Asenosyl-L-Methionine vs Placebo for Osteoarthritis of the Hands
NCT05598580	PHASE4	UNKNOWN	Immunomodulators on HIV-1 Reservoir
NCT00070941	PHASE2/PHASE3	COMPLETED	SAM-e for the Treatment of Depression in Patients With Parkinson’s Disease
NCT00108589	PHASE3	COMPLETED	S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis
NCT00310336	PHASE2/PHASE3	COMPLETED	Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine
NCT00573313	PHASE3	COMPLETED	Effects of SAMe in Patients With Alcoholic Liver Disease
NCT00722124	PHASE2/PHASE3	COMPLETED	S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence
NCT01754714	PHASE3	COMPLETED	Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group
NCT02200029	PHASE3	COMPLETED	Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption
NCT07367724	PHASE2	RECRUITING	Ademetionine in Obstructive Hypertrophic Cardiomyopathy
NCT07495995	PHASE2	NOT_YET_RECRUITING	SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis
NCT00528710	PHASE2	COMPLETED	Efficacy of S-Adenosylmethionine in Fibromyalgia
NCT00851981	PHASE2	COMPLETED	Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease
NCT01912196	PHASE2	COMPLETED	Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)
NCT07582003	PHASE1	NOT_YET_RECRUITING	A Phase I Trial of S-Adenosylmethionine (SAMe) for Chemoprevention of Colorectal Adenomas
NCT00473200	PHASE1	COMPLETED	Effect of S-adenosylmethionine (SAMe) on Blood Levels of Homocysteine
NCT02586285	PHASE1	UNKNOWN	Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma
NCT04623034	PHASE1	COMPLETED	Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine
NCT06026865	Not specified	ACTIVE_NOT_RECRUITING	S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC)
NCT06922669	Not specified	RECRUITING	Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia
NCT07068191	Not specified	RECRUITING	Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
NCT00101452	Not specified	COMPLETED	Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression
NCT00284011	Not specified	COMPLETED	Effect of the Dietary Supplement SAMe on Blood Homocysteine Levels
NCT00694564	Not specified	COMPLETED	Evaluation of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children
NCT00762268	Not specified	COMPLETED	A Trial of SAMe for Treatment-Resistant Bipolar Depression
NCT01806870	Not specified	COMPLETED	Immune Enhancement for Immunological Non-responders to ART
NCT02231333	Not specified	COMPLETED	The Efficacy of S-adenosyl Methionine (SAMe) Versus Pentoxiphylline in Patients With Non-alcoholic Steatohepatitis With Fibrosis
NCT02264860	Not specified	COMPLETED	Researching Alveolar Macrophage Improvements With Supplements in HIV
NCT03178929	Not specified	UNKNOWN	Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma
NCT06427837	Not specified	COMPLETED	Child Snack Variety Study
NCT06766032	Not specified	COMPLETED	Comparison of the Performance and Effectiveness of Two Transfusion-Saving Devices: Cell-Saver and SAME

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).